Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Quality of life
RCT 3-armed trial	148 people with moderate to severe psoriasis Further report of reference	Change in Dermatology Life Quality Index (DLQI) score (from 0 to 30) from baseline to week 12 –11.5 with adalimumab weekly –1.3 with placebo	Adalimumab weekly v placebo: P <0.001 The RCT found similar significantly larger improvements in EQ-5D and SF-36 scores with adalimumab, both weekly and every 2 weeks, compared with placebo	Effect size not calculated	adalimumab
RCT 3-armed trial	148 people with moderate to severe psoriasis Further report of reference	Change in DLQI score (from 0 to 30) from baseline to week 12 –10.8 with adalimumab every 2 weeks –1.3 with placebo	Adalimumab every 2 weeks v placebo: P <0.001 The RCT found similar significantly larger improvements in EQ-5D and SF-36 scores with adalimumab, both weekly and every 2 weeks, compared with placebo	Effect size not calculated	adalimumab